Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016

      Integration of Clarient acquisition on track and progressing well.


      News provided by

      NeoGenomics, Inc.

      Jul 26, 2016, 07:00 ET

      Share this article

      Share this article


      FT. MYERS, Fla., July 26, 2016 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2016.

      Second Quarter 2016 Highlights:

      • 159% increase in consolidated revenue to record $63.1 million
      • 158% increase in clinical genetic testing volume(1)
      • Net income of $413,000 versus net loss of $176,000 in Q2 2015
      • 281% increase in Adjusted EBITDA(2) to $9.2 million
      • Diluted EPS of ($0.07) per share and Adjusted Diluted EPS(2) of $0.04 per share

      Consolidated Revenue for the second quarter was $63.1 million, an increase of 159% over the same period last year.  Clinical genetic test volume(1) grew 158% driven by the inclusion of Clarient's results as well as a 32% year over year increase in base(3) NeoGenomics genetic test volume.  Average revenue-per-test for clinical genetic tests decreased by 5% year over year to $385, primarily due to the inclusion of Clarient's lower average reimbursement rate per test in the combined test mix.  

      Consolidated gross margin for the quarter was 45.3% as compared to 44.4% in last year's second quarter.  Gross margin improved due to a 4.4% reduction in average cost-of-goods-sold per clinical genetic test ("Cost per Test") compared to the second quarter of 2015. 

      Consolidated selling, general and administrative expenses increased by $15.6 million, or 145%, from Quarter 2 2015, primarily as a result of the Clarient acquisition.  Non-cash amortization of intangibles related to the Clarient acquisition and non-cash stock-based compensation expenses accounted for $2.5 million of this increase.        

      Interest expense for the quarter increased by $1.3 million from the second quarter of 2015 as a result of the bank debt incurred to finance the Clarient acquisition.  Cash provided by operating activities was $5.0 million during the quarter.

      Net income before allocation of non-cash preferred stock charges in Quarter 2 was $413,000, versus a net loss of ($176,000) in last year's second quarter. 

      Non-cash "deemed preferred dividends" and non-cash amortization of the "beneficial conversion feature" related to preferred stock held by GE reduced net income attributable to common stockholders by $5.6 million, which resulted in net loss attributable to common stockholders of ($5.2 million) in Quarter 2 2016.  Earnings per share attributable to common stockholders was ($0.07) in Quarter 2, versus ($0.00) per share in last year's second quarter. 

      Adjusted EBITDA(2) was $9.2 million in the second quarter, an increase of 281% over the prior year.  Adjusted Net Income(2) was $3.7 million, a 577% increase over the second quarter of 2015.  Adjusted Diluted EPS(2) was $0.04 per share, versus $0.01 per share in Quarter 2 2015.

      Douglas M. VanOort, the Company's Chairman and CEO, commented, "We are very pleased with our second quarter performance.  Market share gains continue to drive excellent performance in the base NeoGenomics business, and Clarient test volumes have stabilized nicely.  Overall, we are pleased that our revenue growth has been so strong even as we are in the midst of significant integration activities."

      "In addition, our Bio Pharma business grew by 30% on a pro forma basis compared with Quarter 2 last year as we work on innovative projects with many of the world's leading pharmaceutical firms.  The combined capabilities of Clarient and NeoGenomics are making us a more attractive partner for BioPharma clients and their oncology-focused clinical trials.  We are excited about the long-term prospects for this business, which now represents over 10% of our total revenue."

      Mr. VanOort continued, "Our teams are executing integration plans in a disciplined manner, and we are making good progress with the integration of Clarient.  Although we have not yet implemented significant efficiency-related initiatives, we were able to grow Adjusted EBITDA by 281% and increase Adjusted EBITDA margin to 14.5% of revenue.  We expect to realize additional cost synergies later in the year and especially in 2017 as a result of advances in our laboratory information system, adoption of best practices, consolidation of testing facilities and other integration activities currently being executed." 

      Mr. VanOort concluded, "The acquisition of Clarient is clearly providing our company with many more opportunities.  Clients are responding well as client retention remains strong, and the pipeline of new potential clients continues to be robust.  Our ability to provide the best service offerings from each of Clarient and NeoGenomics to our combined client base should provide excellent growth potential as we complete our integration.  We believe this, combined with our continual investments in new products and services, will allow us to continue our strong growth." 

      Full-Year 2016 Financial Outlook:

      NeoGenomics also today reiterated the guidance for fiscal year 2016 that was released with its Quarter 1, 2016 Earnings Release on April 27, 2016.  The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan.  Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company's securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance. 

      Conference Call

      The Company has scheduled a web-cast and conference call to discuss their Q2 2016 results on Tuesday, July 26, 2016 at 11:00 AM EDT.  Interested investors should dial (877) 407-8035 (domestic) and (201) 689-8035 (international) at least five minutes prior to the call.  A replay of the conference call will be available until 11:59 PM on August 9, 2016 and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international).  The playback conference ID Number is 10043.  The web-cast may be accessed under the Investor Relations section of our website at http://neogenomics.com/ or http://investorcalendar.com/IC/CEPage.asp?ID=175124.  An archive of the web-cast will be available until 11:59 PM on October 26, 2016.

      About NeoGenomics, Inc.

      NeoGenomics, Inc. specializes in cancer genetics testing and information services.  The Company provides one of the most comprehensive oncology-focused testing menus in the world for Physicians to help them diagnose and treat cancer.  The Company's BioPharma division serves pharmaceutical clients in clinical trials and drug development.   

      Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Tampa and Fort Myers, Florida; Houston, Texas and Nashville, Tennessee.  NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit http://neogenomics.com/.  

      Forward Looking Statements

      Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including the information set forth in the "Full-Year 2016 Financial Outlook".  These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements as the result of the Company's ability to continue gaining new customers, offer new types of tests, integrate its acquisition of the Clarient business, and otherwise implement its business plan, as well as additional factors discussed under the heading "Risk Factors" and elsewhere in the Company's Annual Report on Form 10-K filed with the SEC on March 15, 2016 as amended on April 18, 2016.  As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC.  In addition, it is the Company's practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.

      Forward-looking statements represent the Company's estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company's estimates as of any subsequent date.  While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

      NeoGenomics, Inc.

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (Unaudited, in thousands)


      ASSETS


      June 30,

      2016





      December 31, 2015

      Cash and cash equivalents


      $

      21,786





      $

      23,420

      Accounts receivable (net of allowance for doubtful accounts of $9,197 and $4,759, respectively)



      53,513






      48,943

      Inventory



      5,545






      5,108

      Other current assets



      6,665






      4,889

      Total current assets



      87,509






      82,360











      Property and equipment (net of accumulated depreciation of $33,858 and $26,534, respectively)



      33,575






      34,577

      Intangible assets, net



      84,164






      87,800

      Goodwill



      146,179






      146,421

      Other assets



      129






      129

      TOTAL ASSETS


      $

      351,556





      $

      351,287











      LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS' EQUITY










      Accounts payable and other current liabilities


      $

      29,616





      $

      26,055

      Short term portion of capital leases and senior debt



      5,337






      14,003

           Total Current liabilities



      34,953






      40,058











      Long-term Liabilities:










        Long term portion of capital leases and senior debt



      56,986






      57,376

        Deferred income tax liability, net



      16,249






      15,741

      Total long-term liabilities



      73,235






      73,117











      TOTAL LIABILITIES



      108,188






      113,175











      Series A Redeemable Convertible Preferred Stock



      39,735






      28,602

      Total Stockholders' equity



      203,633






      209,510

      TOTAL LIABILITIES,  SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY


      $

      351,556





      $

      351,287















      NeoGenomics, Inc.

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

      (in thousands, except per share amounts)

      (Unaudited)




      For the Three Months Ended June 30,



      For the Six Months Ended

      June 30,




      2016



      2015



      2016



      2015


      Net Revenue

















      Clinical testing


      $

      56,316



      $

      24,055



      $

      110,936



      $

      46,894


      BioPharma & research



      6,813




      315




      11,896




      502


      Total Revenue



      63,129




      24,370




      122,832




      47,396



















           Cost of revenue



      34,524




      13,557




      67,055




      27,040


      Gross Profit



      28,605




      10,813




      55,777




      20,356



















      Operating expenses:

















      General and administrative



      18,779




      7,075




      36,785




      13,598


      Research and development



      1,306




      803




      2,752




      1,471


      Sales and marketing



      6,327




      2,907




      12,127




      5,821


      Total operating expenses



      26,412




      10,785




      51,664




      20,890


      Income (Loss) From Operations



      2,193




      28




      4,113




      (534)



















      Interest expense



      1,448




      189




      3,040




      384


      Income (loss) before taxes



      745




      (161)




      1,073




      (918)


      Income tax expense



      332




      15




      505




      19


      Net Income (Loss)



      413




      (176)




      568




      (937)



















      Deemed dividends on preferred stock



      1,840




      —




      3,680




      —


      Amortization of preferred stock
       beneficial conversion feature



      3,727




      —




      7,453




      —


      Net (Loss) Attributable to Common Stockholders


      $

      (5,154)



      $

      (176)



      $

      (10,565)



      $

      (937)



















      Loss per Common Share:

















      Basic


      $

      (0.07)



      $

      (0.00)



      $

      (0.14)



      $

      (0.02)


      Diluted


      $

      (0.07)



      $

      (0.00)



      $

      (0.14)



      $

      (0.02)



















      Weighted Average Shares Used in Computation of Earnings per Common Share:

















      Basic



      77,448




      60,425




      76,758




      60,352


      Diluted



      77,448




      60,425




      76,758




      60,352



      NeoGenomics, Inc.

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

      (Unaudited, in thousands) 




            For the six months ended June 30,


       CASH FLOWS FROM OPERATING ACTIVITIES


      2016



      2015


      Net income (loss)


      $

      568



      $

      (937)


      Adjs. to reconcile net income (loss) to net cash provided by operating activities: 






      Depreciation



      7,329




      3,249


      Amortization of debt issue costs



      358




      -


      Amortization of intangible assets



      3,636




      190


      Non-cash warrant and stock based compensation



      2,337




      1,020


      Provision for bad debts



      5,434




      1,303


      Changes in assets and liabilities, net



      (7,567)




      (2,928)


      NET CASH PROVIDED BY OPERATING ACTIVITIES



      12,095




      1,897











      CASH FLOWS FROM INVESTING ACTIVITIES









      Purchases of property and equipment



      (3,425)




      (1,180)


      NET CASH USED IN INVESTING ACTIVITIES



      (3,425)




      (1,180)











      CASH FLOWS FROM FINANCING ACTIVITIES









      Repayments to revolving credit facility, net



      (10,044)




      -


      Repayment of capital lease obligations, loans



      (2,611)




      (1,833)


      Issuance of common stock



      2,532




      379


      Payments of equity issue costs



      (181)




      -


      NET CASH USED IN FINANCING ACTIVITIES



      (10,304)




      (1,454)











      NET DECREASE IN CASH AND CASH EQUIVALENTS



      (1,634)




      (737)











      CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD



      23,420




      33,689


      CASH AND CASH EQUIVALENTS, END OF PERIOD


      $

      21,786



      $

      32,952











      SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

      Interest paid


      $

      2,691



      $

      417


      Income taxes paid


      $

      222



      $

      20




      SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING INFORMATION:

      Equipment acquired under capital lease obligations


      $

      2,585



      $

      3,400


      Use of non-GAAP Financial Measures

      The Company's financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States of America (GAAP) and using certain non-GAAP financial measures.  Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of core operating results across reporting periods.  Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the Company's business. Management believes that these non-GAAP financial measures enable investors to evaluate our operating results and future prospects in the same manner as management.  The non-GAAP financial measures do not replace the presentation of GAAP financial results and should only be used as a supplement to and not as a substitute for the Company's financial results presented in accordance with GAAP.  There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not therefore present the full measure of the Company's recorded costs against its net revenue.  In addition, the Company's definition of the non-GAAP financial measures below may differ from non-GAAP measures used by other companies. 

      Definitions of non-GAAP measures

      Non – GAAP Adjusted EBITDA

      "Adjusted EBITDA" is defined by NeoGenomics as net income from continuing operations before: (i) interest expense, (ii) tax expense, (iii) depreciation and amortization expense, (iv) non-cash, stock-based compensation expense, and if applicable in a reporting period (v) acquisition related transaction expenses and other significant non-recurring or non-operating (income) or expenses.

      Non – GAAP Adjusted Net Income

      "Adjusted Net Income" is defined by NeoGenomics as net income available to common shareholders from continuing operations plus: (i) non-cash amortization of customer lists and other intangible assets, (ii) non-cash, stock-based compensation expense, (iii) non-cash deemed dividends on preferred stock, (iv) non-cash amortization of preferred stock beneficial conversion feature, and if applicable in a reporting period (v) acquisition related transaction expenses and other significant non-recurring or non-operating (income) or expenses. 

      Non-GAAP Adjusted EPS

      "Adjusted EPS" is defined by NeoGenomics as Adjusted Net Income divided by Adjusted Basic Shares (Adjusted Basic EPS) and Adjusted Diluted Shares outstanding (Adjusted Diluted EPS).  Adjusted Basic Shares and Adjusted Diluted Shares include the weighted average number of common shares that would be outstanding if the preferred stock were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period.  In addition, If GAAP Net Income is negative and Adjusted Net Income is positive, Adjusted Diluted Shares will also include any options or warrants that would be outstanding as dilutive instruments using the treasury stock method. 

      Basis for Non-GAAP Adjustments

      NeoGenomics basis for excluding certain expenses (income) from GAAP financial measures, are outlined below:

      • Amortization of intangible assets –The intangible assets that give rise to this amortization expense relate to acquisitions, and the amounts allocated to such intangible assets and the terms of amortization vary by acquisition and type of asset.  NeoGenomics excludes these items to provide a consistent basis for comparing operating results across reporting periods, pre and post-acquisition.  
      • Stock-based compensation expenses – Although stock-based compensation is an important aspect of the compensation paid to NeoGenomics employees, the related expense is substantially driven by changes in the Company's stock price in any given quarter, which can fluctuate significantly from quarter to quarter and result in large positive or negative impacts to total operating expenses.  The variable accounting treatment causing expense to be driven by changes in quarterly stock price is required because many of the company's full-time Physicians reside in California and are classified as consultants rather than employees due to State regulations.  GAAP provides that variable stock based compensation treatment be applied for consultants but not for employees. Without adjusting for these non-cash expenses, the Company believes it would be difficult to compare financial results from core operations across reporting periods on a consistent basis. 
      • Deemed dividends on preferred stock – GAAP accounting for the unique structure of NeoGenomics' Series A Redeemable Preferred Stock requires the Company to assume that such preferred stock will be outstanding for its entire ten year term.   In addition, GAAP requires that the escalating preferred dividend rate over time be accelerated for accounting purposes and amortized on a straight-line basis over the ten-year life of the instrument, irrespective of the minimal contractual requirements for "paid in kind" stock dividends in the early years.  Since such implied dividends are not paid in cash, and since the Company believes that such preferred stock will be redeemed within the first three years it is outstanding, before any significant dividends have accrued under the contractual terms, the Company believes these non-cash expenses are not meaningful in evaluating the operating performance of the Company and it would be misleading to not adjust for such expenses across reporting periods.   
      • Amortization of preferred stock beneficial conversion feature – This significant non-cash expense is also a direct result of the complex GAAP accounting requirements for our Series A Redeemable Preferred Stock.  The Company believes this expense is not meaningful in evaluating the operating performance of the Company, distorts comparisons across reporting periods, and that it would be misleading to not adjust for such expenses across reporting periods. 

      NeoGenomics, Inc.

      Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Adjusted EBITDA

      (Unaudited, in thousands)




      For the three months ended

      June 30,



      For the six months ended

      June 30,




      2016



      2015



      2016



      2015


      Net Income (Loss) (per GAAP)


      $

      413



      $

      (176)



      $

      568



      $

      (937)


      Adjustments to Net Income (Loss):

















      Interest expense



      1,448




      189




      3,040




      384


      Income tax expense



      332




      15




      505




      19


      Amortization of intangibles



      1,610




      97




      3,636




      190


      Depreciation



      3,744




      1,663




      7,329




      3,249


      EBITDA



      7,547




      1,788




      15,078




      2,905


      Further Adjustments to EBITDA:

















      Non-cash stock based compensation



      1,634




      619




      2,337




      1,020


      Adjusted EBITDA (non-GAAP)


      $

      9,181



      $

      2,407



      $

      17,415



      $

      3,925



      NeoGenomics, Inc.

      Reconciliation of GAAP Net Income Available to Common Stockholders to Non-GAAP Adjusted Net Income and GAAP Earnings per Share to Non-GAAP Adjusted Earnings per Share

      (Unaudited, in thousands)




      For the Three Months
      Ended June 30,



      For the Six Months Ended

      June 30,



      2016


      2015



      2016


      2015

      Net income (loss) available to common stockholders (GAAP)


      $

      (5,154)



      $

      (176)



      $

      (10,565)



      $

      (937)

      Adjustments to Net Loss:
















      Amortization of intangibles



      1,610




      97




      3,636




      190

           Deemed dividends on preferred stock



      1,840




      —




      3,680




      —

      Amortization of preferred stock beneficial conversion feature



      3,727




      —




      7,453




      —

           Non-cash stock based compensation expenses



      1,634




      619




      2,337




      1,020

      Adjusted net income (non-GAAP)


      $

      3,657



      $

      540



      $

      6,541



      $

      273

















      Net loss per common share (GAAP)
















           Basic EPS


      $

      (0.07)



      $

      (0.00)



      $

      (0.14)



      $

      (0.02)

           Diluted EPS


      $

      (0.07)



      $

      (0.00)



      $

      (0.14)



      $

      (0.02)

      Adjustments to Loss per Share:
















           Amortization of intangibles


      $

      0.02



      $

      0.00



      $

      0.05



      $

      0.00

           Non-cash stock based compensation expenses


      $

      0.03



      $

      0.01



      $

      0.03



      $

      0.02

           Deemed dividends on preferred stock


      $

      0.02




      —



      $

      0.05




      —

      Amortization of preferred stock beneficial conversion feature


      $

      0.05



      $

      —



      $

      0.10



      $

      —

      Adjusted net income per common share (non-GAAP):
















      Adjusted Basic


      $

      0.04



      $

      0.01



      $

      0.07



      $

      0.00

      Adjusted Diluted


      $

      0.04



      $

      0.01



      $

      0.07



      $

      0.00

















      Weighted average shares used in computation of adjusted earnings per share:
















           GAAP Basic Common Shares outstanding



      77,448




      60,425




      76,758




      60,352

           Weighted Avg. Preferred Shares (as converted)



      14,667




      —




      14,667




      —

                Adjusted Basic Shares outstanding



      92,115




      60,425




      91,425




      60,352

















      Diluted Common Shares (GAAP)



      77,448




      60,425




      76,758




      60,352

      Options and warrants not included in GAAP Diluted Shares (using treasury stock method)



      2,297




      2,826




      1,951




      2,609

           Weighted Avg. Preferred Shares (as converted)



      14,667




      —




      14,667




      —

                 Adjusted Diluted Shares outstanding (non-GAAP)



      94,412




      63,251




      93,376




      62,961



























      Supplemental Information on

      Clinical Genetic(1) Requisitions Received, Tests Performed, Revenue and Cost of Revenue

      (unaudited, in thousands, except test & requisition data and per test & per requisition data)



      For the Three-Months

      Ended June 30,

      For the Six-Months

      Ended June 30,




      Consolidated


      2016


      2015

      % Change



      2016


      2015

      % Change

      Requisitions received (cases)


      90,795


      34,147

      165.9%



      179,619


      65,244

      175.3%

      Number of tests performed


      140,822


      54,632

      157.8%



      275,726


      103,748

      165.8%

      Average number of tests/requisition


      1.55


      1.60

      (3.1%)



      1.54


      1.59

      (3.5%)













      Total clinical genetic testing revenue

      $

      54,249

      $

      22,118

      145.3%


      $

      106,999

      $

      42,615

      151.1%

      Average revenue/requisition

      $

      597

      $

      648

      (7.8%)


      $

      596

      $

      653

      (8.8%)

      Average revenue/test

      $

      385

      $

      405

      (4.9%)


      $

      388

      $

      411

      (5.5%)













      Cost of revenue

      $

      29,153

      $

      11,832

      146.4%


      $

      56,921

      $

      23,415

      143.1%

      Average cost/requisition

      $

      321

      $

      346

      (7.3%)


      $

      317

      $

      359

      (11.7%)

      Average cost/test

      $

      207

      $

      217

      (4.4%)


      $

      206

      $

      226

      (8.5%)














      Supplemental Information on

      PathLogic Requisitions Received, Tests Performed, Revenue and Cost of Revenue

      (unaudited, in thousands, except requisition data and revenue & cost per requisition)



      For the Three-Months

      Ended June 30,

      For the Six-Months

      Ended June 30,




      PathLogic


      2016


      2015

      % Change



      2016


      2015

      % Change

      Requisitions received (cases)


      14,177


      17,039

      (16.8%)



      27,833


      33,700

      (17.4%)













      Total testing revenue

      $

      2,066

      $

      1,937

      6.6%


      $

      3,937

      $

      4,280

      (8.0%)

      Average revenue/requisition

      $

      146

      $

      114

      28.2%


      $

      141

      $

      127

      11.4%













      Cost of revenue

      $

      1,941

      $

      1,673

      16.0%


      $

      3,618

      $

      3,500

      3.4%

      Average cost/requisition

      $

      137

      $

      98

      39.5%


      $

      130

      $

      104

      25.2%














      (1)   Clinical genetic tests exclude tests performed for BioPharma customers and tests performed by PathLogic.

      (2)   NeoGenomics has provided adjusted financial information that has not been prepared in accordance with GAAP, including "Adjusted EBITDA", "Adjusted Net Income", and "Adjusted EPS".  See Company's explanation of and tables for reconciliations to GAAP net income and GAAP EPS.

      (3)   To facilitate year over year comparisons, base NeoGenomics figures exclude the impacts from the consolidation of the PathLogic and Clarient acquisitions.

      SOURCE NeoGenomics, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.